Brown Advisory Inc. Acquires 14,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Brown Advisory Inc. boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 570,258 shares of the company's stock after buying an additional 14,049 shares during the period. Brown Advisory Inc. owned approximately 0.44% of Vaxcyte worth $21,533,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Capital Research Global Investors increased its position in shares of Vaxcyte by 26.8% during the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock worth $508,393,000 after acquiring an additional 1,312,302 shares in the last quarter. Norges Bank acquired a new position in Vaxcyte in the 4th quarter worth $90,069,000. Vanguard Group Inc. increased its holdings in Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock worth $979,184,000 after purchasing an additional 521,204 shares in the last quarter. Paradigm Biocapital Advisors LP raised its stake in shares of Vaxcyte by 57.3% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after purchasing an additional 518,255 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in shares of Vaxcyte in the 4th quarter valued at about $39,846,000. Institutional investors own 96.78% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PCVX. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. The Goldman Sachs Group lowered their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Finally, Bank of America cut their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Trading Up 6.9%

NASDAQ PCVX opened at $35.78 on Thursday. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The stock has a 50 day moving average of $33.28 and a 200-day moving average of $56.16. The company has a market cap of $4.62 billion, a PE ratio of -8.97 and a beta of 1.19.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the previous year, the business posted ($0.85) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.